|
Arresto Biosciences™
is developing medicines for the treatment of cancer and fibrotic
diseases by targeting molecules from the extracellular matrix. Our
approach is drug modality independent and we are pursuing both
biotherapeutic as well as small molecule approaches in our development
activities.
Arresto BioSciences™ recently published a novel drug strategy
that combines the advantages of allosteric modulators of enzymatic
function with the specificity, selectivity, and pharmacologic
properties of antibodies. Arresto BioSciences™ is using this
approach
to develop novel therapeutics for treating conditions such as oncology,
fibrosis and inflammation.
Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric
antibody inhibitor
Hector M. Rodriguez, Maria Vaysberg, Amanda Mikels, Scott McCauley,
Arleene C. Velayo, Carlos Garcia and Victoria Smith
The Journal of Biological Chemistry, in press. Published on May 3, 2010.
http://www.jbc.org/cgi/doi/10.1074/jbc.M109.094136
Stay tuned for more!
|